By: Clare Logan
ALDH7A1 Gene and Epilepsy
What is the ALDH7A1 Gene?
The ALDH7A1 gene provides instructions for making an enzyme called antiquitin, which is essential for the breakdown of the amino acid lysine. When this enzyme functions normally, it prevents the accumulation of certain toxic molecules in the brain. On the other hand, if the enzyme is not functioning properly, these toxic molecules can interfere with vitamin B6-dependent reactions that neurons rely on to communicate effectively.
Vitamin B6 is necessary for the production of several neurotransmitters, including GABA, which helps regulate and calm electrical activity in the brain. When ALDH7A1 is not functioning properly, certain molecules accumulate and disrupt the normal use of vitamin B6 in the brain. Without enough active vitamin B6 to support healthy communication between neurons, brain cells can become unusually excitable, leading to seizures. Variants in ALDH7A1 that cause the enzyme to malfunction lead to a rare genetic epilepsy called pyridoxine-dependent epilepsy (PDE-ALDH7A1). These variants are inherited in an autosomal recessive manner, meaning that a child must receive one altered copy of the gene from each parent to be affected.
ALDH7A1-Related Epilepsy
Epilepsy associated with ALDH7A1 variants typically begins very early in life, most often during the newborn period or infancy, although later onset can occur. The most distinctive feature of this condition is that seizures respond to vitamin B6 treatment, even when they do not improve with standard anti-seizure medications. Infants may experience frequent or severe seizures, jerks, epileptic spasms, or episodes of apnea (a temporary stopping of breathing). In many cases, seizures resolve dramatically after vitamin B6 administration, sometimes within minutes. Because this response can be so striking, a trial of B6 is often recommended for infants who have unexplained or difficult-to-control seizures.
Although seizure control is a major part of this condition, ALDH7A1-related epilepsy extends beyond the seizures themselves. Even when seizures are well managed, the underlying metabolic abnormalities can affect development, learning, motor skills, or behavior. Some children develop typically, especially when treatment begins early, while others may face ongoing developmental challenges. This wide range in outcomes reflects the complexity of how ALDH7A1 deficiency affects the brain.
Research and Treatment
There is currently no cure for ALDH7A1-related epilepsy, but several treatments are available that address both seizures and the underlying biochemical imbalance. Vitamin B6 remains the cornerstone of therapy. Most individuals require lifelong supplementation, and doses are carefully monitored to avoid side effects from excessive vitamin B6 intake.
In recent years, researchers have developed additional strategies to reduce the accumulation of toxic lysine byproducts. These approaches include medical diets with reduced lysine content, specialized metabolic formulas, and the addition of arginine, which competes with lysine for transport and can lower overall lysine levels. When combined with vitamin B6, lysine-reduction therapies may improve long-term developmental outcomes, highlighting the importance of early identification and comprehensive treatment.
Long-term care for individuals with ALDH7A1 variants often involves a team of specialists, including neurologists, metabolic physicians, dietitians, genetic counselors, and developmental therapists. This multidisciplinary approach supports seizure control, nutritional needs, developmental progress, and family education. Ongoing research is focused on refining dietary therapies, identifying biomarkers for early diagnosis, and understanding why developmental outcomes vary, even when seizures are well controlled.
Resources
Bok, L. A., Struys, E., Willemsen, M. A., Been, J. V., & Jakobs, C. (2007). Pyridoxine-dependent seizures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels. Archives of disease in childhood, 92(8), 687–689. https://doi.org/10.1136/adc.2006.103192
Coughlin CR II, van Karnebeek CDM. Pyridoxine-Dependent Epilepsy — ALDH7A1 Deficiency. GeneReviews® [Internet]. University of Washington, Seattle; 1993–2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1486/
Coughlin, C.R., & Gospe, S.M. (2023). Pyridoxine-dependent epilepsy: Current perspectives and questions for future research. Annals of the Child Neurology Society, 1, 24 – 37.
Mills, P. B., Struys, E., Jakobs, C., Plecko, B., Baxter, P., Baumgartner, M., Willemsen, M. A., Omran, H., Tacke, U., Uhlenberg, B., Weschke, B., & Clayton, P. T. (2006). Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nature medicine, 12(3), 307–309. https://doi.org/10.1038/nm1366
van Karnebeek, C. D., Tiebout, S. A., Niermeijer, J., Poll-The, B. T., Ghani, A., Coughlin, C. R., 2nd, Van Hove, J. L., Richter, J. W., Christen, H. J., Gallagher, R., Hartmann, H., & Stockler-Ipsiroglu, S. (2016). Pyridoxine-Dependent Epilepsy: An Expanding Clinical Spectrum. Pediatric neurology, 59, 6–12. https://doi.org/10.1016/j.pediatrneurol.2015.12.013
